Revealing a steroid receptor ligand as a unique PPARγ agonist

Cell Research

Volumn 22, Issue 4, 2012, Pages 746-756

  Lin, Shengchen ^a,b   Han, Ying ^a,b   Shi, Yuzhe ^a   Rong, Hui ^b   Zheng, Songyang ^b   Jin, Shikan ^a   Lin, Shu Yong ^a   Lin, Sheng Cai ^a   Li, Yong ^a,b  

^a XIAMEN UNIVERSITY   (China)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

crystal structure; diabetes; nuclear receptor; PPAR ; steroid compound

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; LIGAND; MIFEPRISTONE; NCOA6 PROTEIN, HUMAN; NUCLEAR RECEPTOR COACTIVATOR;

ADIPOCYTE; ADIPOGENESIS; ANIMAL; ARTICLE; BINDING SITE; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN TERTIARY STRUCTURE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION;

ADIPOCYTES; ADIPOGENESIS; ANIMALS; BINDING SITES; CERCOPITHECUS AETHIOPS; COS CELLS; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; MIFEPRISTONE; NUCLEAR RECEPTOR COACTIVATORS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLIDINEDIONES;

EID: 84859422120     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2011.162     Document Type: Article

References (43)

1. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005; 123:993-999.
2. Wang YX. PPARs: Diverse regulators in energy metabolism and metabolic diseases. Cell Res 2010; 20:124-137.
3. Yki-Jarvinen H. Thiazolidinediones. N Eng J Med 2004; 351:1106-1118.
4. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Eng J Med 2007; 356:2457-2471.
5. Waki H, Park KW, Mitro N, et al. The small molecule harmine is an antidiabetic cell-type-specific regulator of PPARgamma expression. Cell Metab 2007; 5:357-370.
6. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W. From molecular action to physiological outputs: Peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions. Prog Lipid Res 2006; 45:120-159.
7. Glass CK, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006; 6:44-55.
8. Evans RM, Barish GD, Wang YX. PPARs and the complex journey to obesity. Nat Med 2004; 10:355-361.
9. Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: Structure and function. Curr Opin Cell Biol 1998; 10:384-391.
10. Tsukahara T, Tsukahara R, Fujiwara Y, et al. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol Cell 2010; 39:421-432.
11. Li Y, Lambert MH, Xu HE. Activation of nuclear receptors: A perspective from structural genomics. Structure (Camb) 2003; 11:741-746.
12. Jin L, Li Y. Structural and functional insights into nuclear receptor signaling. Adv Drug Deliv Rev 2010; 62:1218-1226.
13. Berger JP, Akiyama TE, Meinke PT. PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26:244-251.
14. Michalik L, Wahli W. Guiding ligands to nuclear receptors. Cell 2007; 129:649-651.
15. Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): Mechanisms of action and clinical uses. Annu Rev Med 1997; 48:129-156.
16. Johanssen S, Allolio B. Mifepristone (RU 486) in Cushing's syndrome. Eur J Endocrinol 2007; 157:561-569.
17. Dubuc PU, Peterson CM. Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. J Pharmacol Exp Ther 1990; 255:976-979.
18. Langley SC, York DA. Effects of antiglucocorticoid RU 486 on development of obesity in obese fa/fa Zucker rats. Am J Physiol 1990; 259:R539-R544.
19. Gettys TW, Watson PM, Taylor IL, Collins S. RU-486 (Mifepristone) ameliorates diabetes but does not correct deficient beta-adrenergic signalling in adipocytes from mature C57BL/6J-ob/ob mice. Int J Obes Relat Metab Disord 1997; 21:865-873.
20. Taylor AI, Frizzell N, McKillop AM, Flatt PR, Gault VA. Effect of RU486 on hepatic and adipocyte gene expression improves diabetes control in obesity-type 2 diabetes. Horm Metab Res 2009; 41:899-904.
21. Li Y, Choi M, Cavey G, et al. Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1. Mol Cell 2005; 17:491-502.
22. Li Y, Suino K, Daugherty J, Xu HE. Structural and biochemical mechanisms for the specificity of hormone binding and coactivator assembly by mineralocorticoid receptor. Mol Cell 2005; 19:367-380.
23. Laue L, Chrousos GP, Loriaux DL, et al. The antiglucocorticoid and antiprogestin steroid RU 486 suppresses the adrenocorticotropin response to ovine corticotropin releasing hormone in man. J Clin Endocrinol Metab 1988; 66:290-293.
24. Leesnitzer LM, Parks DJ, Bledsoe RK, et al. Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry 2002; 41: 6640-6650.
25. Shao D, Lazar MA. Peroxisome proliferator activated receptor gamma, CCAAT/enhancer-binding protein alpha, and cell cycle status regulate the commitment to adipocyte differentiation. J Biol Chem 1997; 272:21473-21478.
26. Bernlohr DA, Angus CW, Lane MD, Bolanowski MA, Kelly TJ Jr. Expression of specific mRNAs during adipose differentiation: Identification of an mRNA encoding a homologue of myelin P2 protein. Proc Natl Acad Sci USA 1984; 81:5468-5472.
27. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, et al. PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996; 15:5336-5348.
28. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA 1997; 94:237-241.
29. Banga A, Unal R, Tripathi P, et al. Adiponectin translation is increased by the PPARgamma agonists pioglitazone and omega-3 fatty acids. Am J Physiol Endocrinol Metab 2009; 296:E480-E489.
30. Gampe RT Jr., Montana VG, Lambert MH, et al. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol Cell 2000; 5:545-555.
31. Chandra V, Huang P, Hamuro Y, et al. Structure of the intact PPAR-gamma-RXR-nuclear receptor complex on DNA. Nature 2008; 456:350-356.
32. Itoh T, Fairall L, Amin K, et al. Structural basis for the activation of PPARgamma by oxidized fatty acids. Nat Struct Mol Biol 2008; 15:924-931.
33. Li Y, Zhang J, Schopfer FJ, et al. Molecular recognition of nitrated fatty acids by PPAR gamma. Nat Struct Mol Biol 2008; 15:865-867.
34. Kauppi B, Jakob C, Farnegardh M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003; 278:22748-22754.
35. Raaijmakers HC, Versteegh JE, Uitdehaag JC. The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation. J Biol Chem 2009; 284:19572-19579.
36. Jacobson PB, von Geldern TW, Ohman L, et al. Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes. J Pharmacol Exp Ther 2005; 314:191-200.
37. de Souza CJ, Eckhardt M, Gagen K, et al. Effects of pioglitazone on adipose tissue remodeling within the setting of obesity and insulin resistance. Diabetes 2001; 50:1863-1871.
38. Chao L, Marcus-Samuels B, Mason MM, et al. Adipose tissue is required for the antidiabetic, but not for the hypolipidemic, effect of thiazolidinediones. J Clin Invest 2000; 106:1221-1228.
39. Miles PD, Barak Y, He W, Evans RM, Olefsky JM. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 2000; 105:287-292.
40. Reginato MJ, Bailey ST, Krakow SL, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferatoractivated receptor gamma-activating properties. J Biol Chem 1998; 273:32679-32684.
41. Rocchi S, Picard F, Vamecq J, et al. A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 2001; 8:737-747.
42. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol 1997; 276:307-326.
43. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr 2004; 60:2126-2132.